Robert Musslewhite

Robert Musslewhite is currently Chairman of the Governors Board at St. Albans School since 2013.
He serves as Independent Director at CoStar Group, Inc. since 2019.
He is Director at Ascend Learning LLC since 2018, Miriam’s Kitchen, Immunomedics, Inc. since 2020, Autolus Therapeutics Plc since 2024, ADC Therapeutics America, Inc. since 2023, and Iodine Software LLC since 2022.
He is Independent Director at Cardinal Health, Inc. starting in 2025.
He is a member of The Economic Club of Washington and Young Presidents' Organization (Washington).
Formerly, he was Chairman and Chief Executive Officer at The Advisory Board Co. from 2013 to 2017 and at The Advisory Board Co. (United Kingdom) from 2017 to 2019.
He was Chief Executive Officer at OptumInsight, Inc. from 2019 to 2022 and at Optum360 LLC in 2019.
He was President and Chief Executive Officer at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2019 and at Climb Bio, Inc. from 2020 to 2023.
He was Chief Executive Officer and Director at Definitive Healthcare Corp.
from 2022 to 2024 and President and Director at Definitive Healthcare LLC from 2021 to 2022.
He was Chief Commercial Officer and Executive Vice President at Juno Therapeutics, Inc. from 2015 to 2018.
He was Associate Principal at McKinsey & Co., Inc. from 1997 to 2003.
He was Director at Evolent Health, Inc. from 2011 to 2016 and at Clovis Oncology, Inc. from 2018 to 2022.
He also held director roles at SNL Financial LC and Chinook Therapeutics, Inc. Education includes an undergraduate degree from Princeton University conferred in 1992.